ID

44797

Description

Study of Oral IXAZOMIB in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01335685

Link

https://clinicaltrials.gov/show/NCT01335685

Keywords

  1. 11/30/21 11/30/21 - Tabea Kampen
Copyright Holder

Millennium Pharmaceuticals, Inc.

Uploaded on

November 30, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Myeloma NCT01335685

Eligibility Multiple Myeloma NCT01335685

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI [1]
C1512693
male or female patient for whom standard melphalan prednisone (mp) treatment is indicated and who is not a candidate for high-dose therapy plus stem cell transplantation (hdt-sct) for 1 of the following reasons: the patient is 65 years of age or older or the patient is less than 65 years of age but has significant comorbid condition(s) that are likely to have a negative impact on tolerability of hdt-sct
Description

Candidate for melphalan prednisone treatment

Data type

boolean

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C0025241
UMLS CUI [1,3]
C0032952
UMLS CUI [2,1]
C0444956
UMLS CUI [2,2]
C0010858
UMLS CUI [2,3]
C1831743
UMLS CUI [2,4]
C1272460
UMLS CUI [2,5]
C0001779
UMLS CUI [2,6]
C0009488
symptomatic multiple myeloma or asymptomatic myeloma with myeloma-related organ damage diagnosed according to standard criteria
Description

Diagnosis of multiple myeloma

Data type

boolean

Alias
UMLS CUI [1]
C0026764
measurable disease as specified in study protocol
Description

Measureable myeloma

Data type

boolean

Alias
UMLS CUI [1]
C1513041
eastern cooperative oncology group (ecog) performance status of 0 to 2
Description

ECOG

Data type

boolean

Alias
UMLS CUI [1]
C1520224
must have adequate hematologic, liver, and renal function
Description

Organ function

Data type

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0232804
UMLS CUI [1,3]
C0232741
female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse
Description

No pregnancy

Data type

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0015787
UMLS CUI [3,1]
C0700589
UMLS CUI [3,2]
C0036899
UMLS CUI [3,3]
C0009253
male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse
Description

Contraception - male patients

Data type

boolean

Alias
UMLS CUI [1]
C0004764
UMLS CUI [2]
C0036899
voluntary written consent
Description

Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion criteria
Description

Exclusion criteria

Alias
UMLS CUI [1]
C0680251
peripheral neuropathy that is greater or equal to grade 2
Description

Peripheral neuropathy

Data type

boolean

Alias
UMLS CUI [1]
C0031117
female patients who are lactating or pregnant
Description

Pregnancy and breastfeeding

Data type

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
major surgery or radiotherapy within 14 days before the first dose of study drug
Description

Pretreatment

Data type

boolean

Alias
UMLS CUI [1,1]
C0679637
UMLS CUI [1,2]
C0521116
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0521116
uncontrolled infection requiring systematic antibiotics
Description

Infection

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205318
diarrhea (> grade 1)
Description

Diarrhea

Data type

boolean

Alias
UMLS CUI [1]
C0011991
prior systemic therapy for multiple myeloma, including investigational drugs (prior treatment with corticosteroids or localized radiation therapy dose not disqualify the patient)
Description

Prior systemic therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0026764
UMLS CUI [1,3]
C1514463
UMLS CUI [2]
C0013230
central nervous system involvement
Description

CNS

Data type

boolean

Alias
UMLS CUI [1]
C4050309
cardiac status as described in protocol
Description

Cardiac status

Data type

boolean

Alias
UMLS CUI [1]
C1999091
known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption or tolerance of ixazomib - diagnosis of smoldering multiple myeloma, waldenstrom's macroglobulinemia, poems syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
Description

Absorption and tolerance of ixazomib

Data type

boolean

Alias
UMLS CUI [1,1]
C0017178
UMLS CUI [1,2]
C0524722
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C0392678
UMLS CUI [1,5]
C0237442
UMLS CUI [1,6]
C0175795
UMLS CUI [1,7]
C3273711
known human immunodeficiency virus (hiv) positive, hepatitis b surface antigen-positive status, or known or suspected active hepatitis c infection
Description

Infection and immunodeficiency

Data type

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0149709
UMLS CUI [3,1]
C0019196
UMLS CUI [3,2]
C0009450
UMLS CUI [3,3]
C0205177
diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ
Description

Other malignancy

Data type

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0006826
UMLS CUI [2]
C0543478
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0007099
UMLS CUI [4,3]
C1522326
serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
Description

Comorbidities

Data type

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0004936

Similar models

Eligibility Multiple Myeloma NCT01335685

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI [1])
Candidate for melphalan prednisone treatment
Item
male or female patient for whom standard melphalan prednisone (mp) treatment is indicated and who is not a candidate for high-dose therapy plus stem cell transplantation (hdt-sct) for 1 of the following reasons: the patient is 65 years of age or older or the patient is less than 65 years of age but has significant comorbid condition(s) that are likely to have a negative impact on tolerability of hdt-sct
boolean
C3146298 (UMLS CUI [1,1])
C0025241 (UMLS CUI [1,2])
C0032952 (UMLS CUI [1,3])
C0444956 (UMLS CUI [2,1])
C0010858 (UMLS CUI [2,2])
C1831743 (UMLS CUI [2,3])
C1272460 (UMLS CUI [2,4])
C0001779 (UMLS CUI [2,5])
C0009488 (UMLS CUI [2,6])
Diagnosis of multiple myeloma
Item
symptomatic multiple myeloma or asymptomatic myeloma with myeloma-related organ damage diagnosed according to standard criteria
boolean
C0026764 (UMLS CUI [1])
Measureable myeloma
Item
measurable disease as specified in study protocol
boolean
C1513041 (UMLS CUI [1])
ECOG
Item
eastern cooperative oncology group (ecog) performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
must have adequate hematologic, liver, and renal function
boolean
C0221130 (UMLS CUI [1,1])
C0232804 (UMLS CUI [1,2])
C0232741 (UMLS CUI [1,3])
No pregnancy
Item
female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse
boolean
C0232970 (UMLS CUI [1])
C0015787 (UMLS CUI [2])
C0700589 (UMLS CUI [3,1])
C0036899 (UMLS CUI [3,2])
C0009253 (UMLS CUI [3,3])
Contraception - male patients
Item
male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse
boolean
C0004764 (UMLS CUI [1])
C0036899 (UMLS CUI [2])
Consent
Item
voluntary written consent
boolean
C0021430 (UMLS CUI [1])
Item Group
Exclusion criteria
C0680251 (UMLS CUI [1])
Peripheral neuropathy
Item
peripheral neuropathy that is greater or equal to grade 2
boolean
C0031117 (UMLS CUI [1])
Pregnancy and breastfeeding
Item
female patients who are lactating or pregnant
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
Pretreatment
Item
major surgery or radiotherapy within 14 days before the first dose of study drug
boolean
C0679637 (UMLS CUI [1,1])
C0521116 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0521116 (UMLS CUI [2,2])
Infection
Item
uncontrolled infection requiring systematic antibiotics
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Diarrhea
Item
diarrhea (> grade 1)
boolean
C0011991 (UMLS CUI [1])
Prior systemic therapy
Item
prior systemic therapy for multiple myeloma, including investigational drugs (prior treatment with corticosteroids or localized radiation therapy dose not disqualify the patient)
boolean
C1515119 (UMLS CUI [1,1])
C0026764 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2])
CNS
Item
central nervous system involvement
boolean
C4050309 (UMLS CUI [1])
Cardiac status
Item
cardiac status as described in protocol
boolean
C1999091 (UMLS CUI [1])
Absorption and tolerance of ixazomib
Item
known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption or tolerance of ixazomib - diagnosis of smoldering multiple myeloma, waldenstrom's macroglobulinemia, poems syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
boolean
C0017178 (UMLS CUI [1,1])
C0524722 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0392678 (UMLS CUI [1,4])
C0237442 (UMLS CUI [1,5])
C0175795 (UMLS CUI [1,6])
C3273711 (UMLS CUI [1,7])
Infection and immunodeficiency
Item
known human immunodeficiency virus (hiv) positive, hepatitis b surface antigen-positive status, or known or suspected active hepatitis c infection
boolean
C0019699 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
C0019196 (UMLS CUI [3,1])
C0009450 (UMLS CUI [3,2])
C0205177 (UMLS CUI [3,3])
Other malignancy
Item
diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ
boolean
C0262926 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0543478 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0007099 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
Comorbidities
Item
serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0004936 (UMLS CUI [1,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial